SLS
SELLAS Life Sciences Group, Inc.
$7.83
+1.03%
$1.5B
No data for this timeframe.
Vol
Market Cap$1.5B
Cap SizeSmall Cap
Inst. Holders50 funds
Inst. Value$238.6M
Inst. Activity15 buys / 2 sells
Reddit Sentiment56° Neutral
SEC Reports3
Press Releases3
Recent Activity
Jun 2, 2026
SEC
SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise proceeds during April and May
8-K — Impact 3/10
May 12, 2026
SEC
SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS) vs consensus $-0.06, a 16.7% beat. The key catalys
8-K — Impact 6/10
Apr 23, 2026
SEC
SELLAS Life Sciences Group, Inc. (SLS) has filed its definitive proxy statement for the 2026 Annual Meeting. The filing
DEFA14A — Impact 2/10
Inst.
BlackRock, Inc. — ADD
12,198,410 shares ($51.6M)
Inst.
STATE STREET CORP — DOUBLED
8,396,356 shares ($35.5M)
Jun 11, 2026
short_volume
Short Volume: SLS — 61.9% short (2.0M / 3.3M)
Short: 2,030,939 | Exempt: 15,727 | TRF Vol: 3,280,173 | Short Ratio: 61.9% | Off-exchange volume (d
Mar 19, 2026
Press
SELLAS Life Sciences reported financial results for 2025, showing reduced net loss and a strong cash position bolstered
Impact 6/10
Mar 17, 2026
Press
SELLAS Life Sciences announced preclinical data for its CDK9 inhibitor SLS009 (tambiciclib) showing potent apoptosis ind
Impact 5/10
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$10.00 (Mar 2026)
Current $7.83
Low $10.00
Median $10.00
High $10.00
2 analysts
$10.00
$10.00
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 12, 2026 | Maxim Group | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 ▲ +25.0% | $-0.05 — $-0.05 | 29% YoY | 2 |
| Next Q | $-0.06 ▲ +25.0% | $-0.06 — $-0.05 | 8% YoY | 2 |
| Current FY | $-0.21 ▲ +25.9% | $-0.22 — $-0.20 | 16% YoY | 2 |
| Next FY | $-0.15 ▲ +16.7% | $-0.25 — $-0.05 | 29% YoY | 2 |
Latest Reports
NEUTRAL
8-K
3/10
SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise proceeds during April and May
Jun 2, 2026
NEUTRAL
8-K
6/10
SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS) vs consensus $-0.06, a 16.7% beat. The key catalys
May 12, 2026
MIXED
Press
6/10
SELLAS Life Sciences reported financial results for 2025, showing reduced net loss and a strong cash position bolstered
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $51.6M | ADD |
| STATE STREET CORP | $35.5M | DOUBLED |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $32.2M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $31.8M | — |
| CITADEL ADVISORS LLC | $18.5M | DOUBLED |
Reddit Sentiment
56°▲
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $238.6M total value (56,378,552 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, SUSQUEHANNA. Net buying activity: 15 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 12,198,410 | $51.6M | 21.6% | ADD +61.8% |
| 2 | STATE STREET CORP | 8,396,356 | $35.5M | 14.9% | DOUBLED +283.7% |
| 3 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 7,624,100 | $32.2M | 13.5% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 7,525,929 | $31.8M | 13.3% | — |
| 5 | CITADEL ADVISORS LLC | 4,368,200 | $18.5M | 7.7% | DOUBLED +128.7% |
| 6 | MARSHALL WACE, LLP | 2,037,162 | $8.6M | 3.6% | ADD +52.0% |
| 7 | JONES FINANCIAL COMPANIES LLLP | 1,675,077 | $7.3M | 3.1% | — |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,462,806 | $6.2M | 2.6% | — |
| 9 | MORGAN STANLEY | 1,336,293 | $5.7M | 2.4% | ADD +50.0% |
| 10 | VANGUARD FIDUCIARY TRUST CO | 1,202,839 | $5.1M | 2.1% | — |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 960,400 | $4.1M | 1.7% | — |
| 12 | Invesco Ltd. | 698,080 | $3.0M | 1.2% | DOUBLED +1209.9% |
| 13 | Nuveen, LLC | 670,974 | $2.8M | 1.2% | TRIM -34.5% |
| 14 | BANK OF AMERICA CORP /DE/ | 641,683 | $2.7M | 1.1% | DOUBLED +535.7% |
| 15 | GOLDMAN SACHS GROUP INC | 555,913 | $2.4M | 1.0% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 480,604 | $2.0M | 0.9% | ADD +38.9% |
| 17 | CITADEL ADVISORS LLC | 449,800 | $1.9M | 0.8% | DOUBLED +128.7% |
| 18 | NOMURA HOLDINGS INC | 436,700 | $1.8M | 0.8% | — |
| 19 | TWO SIGMA INVESTMENTS, LP | 403,165 | $1.7M | 0.7% | DOUBLED +642.0% |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 397,056 | $1.7M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 7,541,054 | 12,198,410 | +61.8% | $51.6M | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 2,188,171 | 8,396,356 | +283.7% | $35.5M | 2026-Q1 |
| MARSHALL WACE, LLP | ADD | 1,340,668 | 2,037,162 | +52.0% | $8.6M | 2026-Q1 |
| MORGAN STANLEY | ADD | 890,929 | 1,336,293 | +50.0% | $5.7M | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 53,293 | 698,080 | +1209.9% | $3.0M | 2026-Q1 |
| Nuveen, LLC | TRIM | 1,023,961 | 670,974 | -34.5% | $2.8M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 100,935 | 641,683 | +535.7% | $2.7M | 2026-Q1 |
| RHUMBLINE ADVISERS | ADD | 129,309 | 194,198 | +50.2% | $821.5K | 2026-Q1 |
| DEUTSCHE BANK AG\ | ADD | 91,688 | 137,646 | +50.1% | $582.2K | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 57,547 | 98,289 | +70.8% | $411.8K | 2026-Q1 |
| MetLife Investment Management, LLC | DOUBLED | 27,181 | 94,255 | +246.8% | $398.7K | 2026-Q1 |
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 29,244 | 38,470 | +31.5% | $162.7K | 2026-Q1 |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 21,034 | 29,262 | +39.1% | $123.8K | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 9,560 | 18,006 | +88.3% | $76.2K | 2026-Q1 |
| FMR LLC | DOUBLED | 7,495 | 15,561 | +107.6% | $65.8K | 2026-Q1 |
| BLAIR WILLIAM & CO/IL | TRIM | 26,002 | 14,005 | -46.1% | $59.2K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 63,026 | 122,120 | +93.8% | $517.00 | 2026-Q1 |
| BlackRock, Inc. | ADD | 5,686,886 | 7,541,054 | +32.6% | $28.4M | 2025-Q4 |
| STATE STREET CORP | ADD | 1,360,914 | 2,188,171 | +60.8% | $8.2M | 2025-Q4 |
| MARSHALL WACE, LLP | TRIM | 2,357,999 | 1,340,668 | -43.1% | $5.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 145,856 | 1,082,207 | +642.0% | $4.1M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 294,106 | 408,401 | +38.9% | $1.5M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 75,867 | 299,305 | +294.5% | $1.1M | 2025-Q4 |
| Mariner, LLC | ADD | 108,806 | 159,150 | +46.3% | $600.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 42,150 | 100,935 | +139.5% | $380.5K | 2025-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.7/10.
NEUTRAL
8-K
3/10
SELLAS Life Sciences disclosed it received approximately $28.7 million in warrant exercise proceeds
Jun 2, 2026
NEUTRAL
8-K
6/10
SELLAS reported Q1 2026 results with a net loss of $8.4M ($-0.05 EPS) vs consensus $-0.06, a 16.7% b
May 12, 2026
NEUTRAL
DEFA14A
2/10
SELLAS Life Sciences Group, Inc. (SLS) has filed its definitive proxy statement for the 2026 Annual
Apr 23, 2026
MIXED
6/10
SELLAS Life Sciences reported financial results for 2025, showing reduced net loss and a strong cash
Mar 19, 2026
MIXED
5/10
SELLAS Life Sciences announced preclinical data for its CDK9 inhibitor SLS009 (tambiciclib) showing
Mar 17, 2026
BULLISH
7/10
SELLAS Life Sciences has enrolled the first patient in a Phase 2 trial for its CDK9 inhibitor SLS009
Mar 12, 2026
Historical analyst distribution (last covering-analyst action Mar 2026): 83% buy across 6 analysts — 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$10.00 mean target (Mar 2026)
$10.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $7.83 |
| Target Low | $10.00 |
| Target Mean | $10.00 |
| Target Median | $10.00 |
| Target High | $10.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.05 | $-0.05 | 28.6% | +25.0% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.06 | $-0.06 | $-0.05 | 8.3% | +25.0% | 1↑ 1↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.21 | $-0.22 | $-0.20 | 16.0% | +25.9% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.15 | $-0.25 | $-0.05 | 28.6% | +16.7% | 2↑ 1↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $-0.070 | +0.020 |
| 30d ago | $-0.067 | +0.017 |
| 60d ago | $-0.067 | +0.017 |
| 90d ago | $-0.067 | +0.017 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
56°
Neutral
Bearish
Neutral
Bullish
31 mentions
11 bullish
7 bearish
30 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 10, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 9, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Jun 7, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 2, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 26, 2026 | 2 | 50° Neutral | 0 | 0 | 2 |
| May 26, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 17, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 16, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
SLS, ONDS, DRTS and HOVR
▲ 1
💬 1
⚡ 0.5
Thoughts on HOVR, SLS, DRTS and ONDS
▲ 1
💬 0
⚡ 0.5
ROTH CANCER YOLO (SLS)
▲ 1
💬 0
⚡ 0.5
Hot take, looking for opinions.
▲ 1
💬 1
⚡ 0.5
Full porting $SLS
▲ 1
💬 0
⚡ 0.5
SLS, NBIS or SNXX for this coming week
▲ 1
💬 0
⚡ 0.5
SLS, NBIS or SNXX for this coming week
▲ 1
💬 0
⚡ 0.5
From the sellaslifesciences community on Reddit: TD Cowan / SLS Fireside Chat - 27 May 2026 / 09:00 a.m. (EST)
▲ 1
💬 0
⚡ 0.5
From the sellaslifesciences community on Reddit: TD Cowan / SLS Fireside Chat - 27 May 2026 / 09:00 a.m. (EST)
▲ 1
💬 0
⚡ 0.5
How do you feel about SLS and IBRX?
▲ 1
💬 1
⚡ 0.5
All in on cancer $SLS
▲ 1
💬 1
⚡ 0.5
Sell some Intel to take a larger position in SLS? I’m OKAY with the greed, but I’m not sure my logic is sound.
▲ 1
💬 0
⚡ 0.5
Hold Intel vs buying more SLS . I’m leaning greed, but have I’m not sure about my logic.
▲ 1
💬 0
⚡ 0.5
Time to short squeeze $SLS!
▲ 1
💬 1
⚡ 0.5
NUAI, CING, SLS or FEMY…
▲ 1
💬 1
⚡ 0.5
Portfolio in the middle of doom and gloom for SaaS.
▲ 1
💬 1
⚡ 0.5
I need $1m by July...or else
▲ 1
💬 1
⚡ 0.5
Jun 11, 2026
short_volume
Short Volume: SLS — 61.9% short (2.0M / 3.3M)
Short: 2,030,939 | Exempt: 15,727 | TRF Vol: 3,280,173 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: SLS — 56.9% short (2.0M / 3.5M)
Short: 1,982,150 | Exempt: 22,903 | TRF Vol: 3,486,326 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: SLS — 55.2% short (2.1M / 3.8M)
Short: 2,104,611 | Exempt: 2,657 | TRF Vol: 3,810,941 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: SLS — 59.8% short (1.8M / 3.0M)
Short: 1,778,980 | Exempt: 224,054 | TRF Vol: 2,975,054 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: SLS — 55.3% short (2.0M / 3.6M)
Short: 2,015,132 | Exempt: 72,711 | TRF Vol: 3,645,296 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: SLS — 63.2% short (2.5M / 3.9M)
Short: 2,490,896 | Exempt: 6,781 | TRF Vol: 3,941,000 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: SLS — 64.5% short (3.5M / 5.5M)
Short: 3,536,554 | Exempt: 11,361 | TRF Vol: 5,486,002 | Short Ratio: 64.5% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: SLS — 59.4% short (2.2M / 3.7M)
Short: 2,221,975 | Exempt: 43,052 | TRF Vol: 3,738,809 | Short Ratio: 59.4% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: SLS — 58.7% short (3.5M / 6.0M)
Short: 3,545,788 | Exempt: 79,561 | TRF Vol: 6,040,567 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: SLS — 60.9% short (3.4M / 5.6M)
Short: 3,421,121 | Exempt: 435,905 | TRF Vol: 5,618,914 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
May 21, 2026
short_volume
Short Volume: SLS — 61.8% short (8.4M / 13.6M)
Short: 8,425,002 | Exempt: 555,823 | TRF Vol: 13,622,871 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: SLS — 64.1% short (6.4M / 10.0M)
Short: 6,436,777 | Exempt: 54,857 | TRF Vol: 10,046,549 | Short Ratio: 64.1% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: SLS — 55.0% short (2.2M / 4.0M)
Short: 2,206,446 | Exempt: 19,932 | TRF Vol: 4,008,262 | Short Ratio: 55.0% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: SLS — 59.2% short (2.7M / 4.6M)
Short: 2,723,211 | Exempt: 36,984 | TRF Vol: 4,600,489 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: SLS — 60.5% short (2.6M / 4.2M)
Short: 2,570,714 | Exempt: 24,508 | TRF Vol: 4,247,506 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)